Certara, Inc. (NASDAQ:CERT – Get Free Report) has been given an average recommendation of “Hold” by the eleven ratings firms that are presently covering the stock, Marketbeat reports. Seven research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $20.06.
Several equities analysts have recently issued reports on the company. SVB Leerink initiated coverage on Certara in a report on Monday, February 26th. They issued a “market perform” rating and a $19.00 target price for the company. Leerink Partnrs reiterated a “market perform” rating on shares of Certara in a research report on Monday, February 26th. Barclays raised their price target on Certara from $16.00 to $18.00 and gave the company an “equal weight” rating in a research report on Thursday, January 25th. KeyCorp upgraded Certara from a “sector weight” rating to an “overweight” rating and set a $23.00 price target on the stock in a research report on Wednesday, April 10th. Finally, UBS Group raised their price objective on Certara from $17.00 to $20.00 and gave the company a “neutral” rating in a research note on Friday, March 1st.
Read Our Latest Analysis on Certara
Insider Buying and Selling at Certara
Institutional Investors Weigh In On Certara
Hedge funds have recently added to or reduced their stakes in the stock. Envestnet Asset Management Inc. boosted its holdings in Certara by 45.3% in the 3rd quarter. Envestnet Asset Management Inc. now owns 335,440 shares of the company’s stock worth $4,877,000 after buying an additional 104,616 shares during the period. Charles Schwab Investment Management Inc. raised its position in shares of Certara by 5.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 607,030 shares of the company’s stock valued at $8,826,000 after buying an additional 32,790 shares in the last quarter. Kayne Anderson Rudnick Investment Management LLC raised its position in Certara by 48.8% in the 3rd quarter. Kayne Anderson Rudnick Investment Management LLC now owns 727,240 shares of the company’s stock worth $10,574,000 after purchasing an additional 238,603 shares during the period. State of New Jersey Common Pension Fund D raised its position in Certara by 31.6% in the 3rd quarter. State of New Jersey Common Pension Fund D now owns 151,785 shares of the company’s stock worth $2,207,000 after purchasing an additional 36,490 shares during the period. Finally, William Blair Investment Management LLC raised its position in Certara by 1.1% in the 3rd quarter. William Blair Investment Management LLC now owns 7,150,914 shares of the company’s stock worth $103,974,000 after purchasing an additional 77,805 shares during the period. 73.96% of the stock is currently owned by hedge funds and other institutional investors.
Certara Trading Up 2.5 %
Shares of CERT stock opened at $16.92 on Monday. The firm has a market capitalization of $2.72 billion, a P/E ratio of -43.38, a P/E/G ratio of 1.64 and a beta of 1.61. Certara has a twelve month low of $11.81 and a twelve month high of $22.65. The company has a quick ratio of 3.26, a current ratio of 3.26 and a debt-to-equity ratio of 0.27. The stock’s fifty day simple moving average is $17.27 and its 200 day simple moving average is $16.72.
Certara (NASDAQ:CERT – Get Free Report) last announced its quarterly earnings data on Thursday, February 29th. The company reported $0.05 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.04). Certara had a negative net margin of 17.02% and a positive return on equity of 4.08%. The business had revenue of $88.01 million during the quarter, compared to analyst estimates of $86.80 million. As a group, sell-side analysts predict that Certara will post 0.29 EPS for the current fiscal year.
About Certara
Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.
See Also
- Five stocks we like better than Certara
- There Are Different Types of Stock To Invest In
- TJX Companies Can Hit New Highs; Double-Digit Upside to Follow
- The 3 Best Blue-Chip Stocks to Buy Now
- A Hidden Gem Retailer With 20% Upside
- How to Invest in Biotech Stocks
- Zoom Stock’s Earnings Volatility Picked Up a Lot of Buyers
Receive News & Ratings for Certara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Certara and related companies with MarketBeat.com's FREE daily email newsletter.